Ascend Advanced Therapies

Quality manufacturing capacity for developers of gene and cell therapies

First Investment: 2023

Biotech and pharmaceutical companies developing innovative gene and cell therapies no longer need to build an in-house capacity to manufacture these therapies. Ascend offers flexible chemistry, manufacturing, and controls (CMC) services for companies working in gene therapy, with an initial focus on Adeno-associated virus (AAV) vectors.

News & Insights

Ascend partners with industry to drive down gene therapy cost for better patient access

In The Media

Financial Times

UK biotech start-up raises $130mn to solve capacity bottleneck

Ascend Advanced Therapies

Explore Companies

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery

Latus Bio

Finding precisely tuned viral vectors for gene therapy in CNS disorders

Radionetics Oncology

Discovering more precise ways to deploy radiopharmaceuticals against solid tumors

DVLP Medicines

Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing